Sonnet BioTherapeutics (SONN) 10-Q 14 Aug 24 2024 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Jun. 30, 2024	Aug. 14, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--09-30
Entity File Number	001-35570
Entity Registrant Name	SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Entity Central Index Key	0001106838
Entity Tax Identification Number	20-2932652
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	100 Overlook Center
Entity Address, Address Line Two	Suite 102
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	(609)
Local Phone Number	375-2227
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	SONN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,202,505
Entity Listing, Par Value Per Share	$ 0.0001

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2024	Sep. 30, 2023
Current assets:
Cash	$ 3,554,331	$ 2,274,259
Prepaid expenses and other current assets	1,053,830	1,677,396
Incentive tax receivable	519,610	786,574
Total current assets	5,127,771	4,738,229
Property and equipment, net	23,733	33,366
Operating lease right-of-use asset	141,813	193,689
Deferred offering costs	15,000	49,988
Other assets	488,480	414,206
Total assets	5,796,797	5,429,478
Current liabilities:
Accounts payable	1,879,013	2,201,999
Accrued expenses and other current liabilities	1,149,492	3,230,922
Current portion of operating lease liability	81,349	73,048
Deferred income		18,626
Total current liabilities	3,109,854	5,524,595
Operating lease liability, net of current portion	68,837	130,863
Total liabilities	3,178,691	5,655,458
Commitments and contingencies (Note 4)
Stockholders’ equity (deficit):
Common stock, $0.0001 par value: 125,000,000 shares authorized; 5,218,505 and 1,750,426 issued and outstanding at June 30, 2024 and September 30, 2023, respectively	522	175
Additional paid-in capital	117,169,976	110,017,598
Accumulated deficit	(114,552,392)	(110,243,753)
Total stockholders’ equity (deficit)	2,618,106	(225,980)
Total liabilities and stockholders’ equity (deficit)	$ 5,796,797	$ 5,429,478

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2024	Sep. 30, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	5,218,505	1,750,426
Common stock, shares outstanding	5,218,505	1,750,426

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Collaboration revenue		$ 36,850	$ 18,626	$ 110,550
Operating expenses:
Research and development	1,727,033	2,409,471	4,538,363	9,972,055
General and administrative	1,801,632	1,542,689	4,156,360	5,330,967
Total operating expenses	3,528,665	3,952,160	8,694,723	15,303,022
Loss from operations	(3,528,665)	(3,915,310)	(8,676,097)	(15,192,472)
Other income			4,327,946
Foreign exchange gain (loss)	23,110	(31,432)	39,512	36,517
Net loss	$ (3,505,555)	$ (3,946,742)	$ (4,308,639)	$ (15,155,955)
Per share information:
Net loss per share, basic	$ (0.70)	$ (2.95)	$ (0.96)	$ (18.98)
Net loss per share, diluted	$ (0.70)	$ (2.95)	$ (0.96)	$ (18.98)
Weighted average shares outstanding, basic	5,037,508	1,335,872	4,481,803	798,711
Weighted average shares outstanding, diluted	5,037,508	1,335,872	4,481,803	798,711

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Sep. 30, 2022	$ 25	$ 88,872,315	$ (91,411,059)	$ (2,538,719)
Balance, shares at Sep. 30, 2022	251,973
Sale of common stock, net of issuance costs	$ 11	4,452,001		4,452,012
Sale of common stock, net of issuance costs, shares	109,841
Net share settlement of warrants
Net share settlement of warrants, shares	137
Share-based compensation		91,617		91,617
Net income (loss)			(5,542,142)	(5,542,142)
Balance at Dec. 31, 2022	$ 36	93,415,933	(96,953,201)	(3,537,232)
Balance, shares at Dec. 31, 2022	361,951
Balance at Sep. 30, 2022	$ 25	88,872,315	(91,411,059)	(2,538,719)
Balance, shares at Sep. 30, 2022	251,973
Net income (loss)				(15,155,955)
Balance at Jun. 30, 2023	$ 175	109,985,291	(106,567,014)	3,418,452
Balance, shares at Jun. 30, 2023	1,744,913
Balance at Dec. 31, 2022	$ 36	93,415,933	(96,953,201)	(3,537,232)
Balance, shares at Dec. 31, 2022	361,951
Sale of common stock, net of issuance costs	$ 56	14,515,912		14,515,968
Sale of common stock, net of issuance costs, shares	557,083
Net share settlement of warrants	$ 1	(1)
Net share settlement of warrants, shares	10,521
Share-based compensation		56,998		56,998
Net income (loss)			(5,667,071)	(5,667,071)
Issuance of common stock on vesting of restricted stock units and restricted stock awards
Issuance of common stock on vesting of restricted stock units and restricted stock awards, shares	2,127
Balance at Mar. 31, 2023	$ 93	107,988,842	(102,620,272)	5,368,663
Balance, shares at Mar. 31, 2023	931,682
Sale of common stock, net of issuance costs	$ 17	1,945,660		1,945,677
Sale of common stock, net of issuance costs, shares	166,364
Net share settlement of warrants	$ 51	(51)
Net share settlement of warrants, shares	508,834
Share-based compensation		50,005		50,005
Net income (loss)			(3,946,742)	(3,946,742)
Issuance of common stock on vesting of restricted stock units and restricted stock awards
Issuance of common stock on vesting of restricted stock units and restricted stock awards, shares	35
Exercise of warrants	$ 14	835		849
Exercise of warrants, shares	137,998
Balance at Jun. 30, 2023	$ 175	109,985,291	(106,567,014)	3,418,452
Balance, shares at Jun. 30, 2023	1,744,913
Balance at Sep. 30, 2023	$ 175	110,017,598	(110,243,753)	(225,980)
Balance, shares at Sep. 30, 2023	1,750,426
Sale of common stock, net of issuance costs	$ 131	3,916,812		3,916,943
Sale of common stock, net of issuance costs, shares	1,306,250
Retirement of shares in connection with reverse stock split
Retirement of shares in connection with reverse stock split, shares	(1,522)
Net share settlement of warrants	$ 1	(1)
Net share settlement of warrants, shares	14,362
Share-based compensation		50,005		50,005
Net income (loss)			(1,168,509)	(1,168,509)
Balance at Dec. 31, 2023	$ 307	113,984,414	(111,412,262)	2,572,459
Balance, shares at Dec. 31, 2023	3,069,516
Balance at Sep. 30, 2023	$ 175	110,017,598	(110,243,753)	(225,980)
Balance, shares at Sep. 30, 2023	1,750,426
Net income (loss)				(4,308,639)
Balance at Jun. 30, 2024	$ 522	117,169,976	(114,552,392)	2,618,106
Balance, shares at Jun. 30, 2024	5,218,505
Balance at Dec. 31, 2023	$ 307	113,984,414	(111,412,262)	2,572,459
Balance, shares at Dec. 31, 2023	3,069,516
Share-based compensation		60,395		60,395
Net income (loss)			365,425	365,425
Issuance of common stock on vesting of restricted stock units and restricted stock awards
Issuance of common stock on vesting of restricted stock units and restricted stock awards, shares	7,885
Exercise of warrants	$ 4	55,996		56,000
Exercise of warrants, shares	35,000
Balance at Mar. 31, 2024	$ 311	114,100,805	(111,046,837)	3,054,279
Balance, shares at Mar. 31, 2024	3,112,401
Sale of common stock, net of issuance costs	$ 4	62,015		62,019
Sale of common stock, net of issuance costs, shares	37,654
Net share settlement of warrants	$ 74	(74)
Net share settlement of warrants, shares	739,950
Share-based compensation		60,395		60,395
Net income (loss)			(3,505,555)	(3,505,555)
Exercise and modification of warrants, net of issuance costs	$ 133	2,946,835		2,946,968
Exercise and modification of warrants, net of issuance costs, shares	1,328,500
Balance at Jun. 30, 2024	$ 522	$ 117,169,976	$ (114,552,392)	$ 2,618,106
Balance, shares at Jun. 30, 2024	5,218,505

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (4,308,639)	$ (15,155,955)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	9,633	9,634
Acquired in-process research and development	12,000	282,000
Amortization of operating lease right-of-use asset	51,876	46,650
Share-based compensation	170,795	198,620
Financing costs related to ChEF Purchase Agreement	370,426
Non-cash financing costs	1,732
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	623,566	(218,940)
Incentive tax receivable	266,964	(31,864)
Other assets	(74,274)	(155,366)
Accounts payable	(455,038)	(1,877,222)
Accrued expenses and other current liabilities	(2,034,243)	264,872
Operating lease liability	(53,725)	(34,609)
Deferred income	(18,626)	(110,549)
Net cash used in operating activities	(5,437,553)	(16,782,729)
Cash flows from investing activities:
Purchase of in-process research and development	(12,000)	(273,250)
Net cash used in investing activities	(12,000)	(273,250)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs	3,899,157	21,024,070
Payment of deferred offering costs	(15,000)
Payment of financing costs related to ChEF Purchase Agreement	(157,500)
Proceeds from exercise and modification of warrants, net of issuance costs	3,002,968	849
Repayments of related party note		(748)
Net cash provided by financing activities	6,729,625	21,024,171
Net increase in cash	1,280,072	3,968,192
Cash, beginning of period	2,274,259	3,052,879
Cash, end of period	3,554,331	7,021,071
Supplemental disclosure of non-cash operating, investing and financing activities:
Net settlement of warrants	75	1,142
ChEF Purchase Agreement financing costs in accounts payable	212,926
In-process research and development in accounts payable and accrued expenses		170,000
Deferred offering costs charged against proceeds from sale of common stock		32,340
Issuance of common stock on vesting of restricted stock units		5
Common stock issuance costs in accounts payable		$ 78,073

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (3,505,555)	$ 365,425	$ (1,168,509)	$ (3,946,742)	$ (5,667,071)	$ (5,542,142)	$ (4,308,639)	$ (15,155,955)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Description of

Organization and Description of Business	9 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Description of business Sonnet BioTherapeutics, Inc. (“Prior Sonnet”) was incorporated as a New Jersey corporation on April 6, 2015. Prior Sonnet completed a merger with publicly-held Chanticleer Holdings, Inc. (“Chanticleer”) on April 1, 2020. After the merger, Chanticleer changed its name to Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”). Sonnet is a clinical stage, oncology-focused biotechnology company with a proprietary platform for innovating biologic medicines of single or bifunctional action. Known as F H H H Sonnet’s lead proprietary asset, SON-1010, is a fully human version of Interleukin 12 (“IL-12”), covalently linked to the F H In January 2023, Sonnet announced a collaboration agreement with Roche for the clinical evaluation of SON-1010 with atezolizumab (Tecentriq®). The companies have entered into a Master Clinical Trial and Supply Agreement (“MCSA”), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (“PROC”) patient setting. Further, the companies will provide SON-1010 and atezolizumab, respectively, for use in the Phase 1b/Phase 2a combination safety, dose-escalation, and proof-of-concept study (SB221). Part 1 of this 2-part study was approved in June 2023 by the local Human Research Ethics Committee in Australia under CT-2023-CTN-01399-1 and the Therapeutic Goods Administration has been notified. In August 2023, the FDA accepted the IND for SB221. The trial consists of a modified 3+3 dose-escalation design in Part 1 to establish the maximum tolerated dose (“MTD”) of SON-1010 with a fixed dose of atezolizumab. Clinical benefit in PROC will be confirmed in an expansion group to establish the recommended Phase 2 dose (“RP2D”). Part 2 of the study will then investigate SON-1010 in combination with atezolizumab, or the standard of care (“SOC”) for PROC in a randomized comparison to show proof-of-concept (“POC”). As part of the ongoing cost-cutting efforts, all antiviral development with SON-1010 has been suspended. The Company acquired the global development rights to its most advanced compound, SON-080, a fully human version of Interleukin 6 (“IL-6”), in April 2020 through its acquisition of the outstanding shares of Relief Therapeutics SA. Sonnet is advancing SON-080 in target indications of Chemotherapy-Induced Peripheral Neuropathy (“CIPN”) and Diabetic Peripheral Neuropathy (“DPN”). Sonnet received approval to initiate an ex-U.S. Phase 1b/2a study with SON-080 in CIPN during the third quarter of 2022. The Data Safety Monitoring Board (“DSMB”) overseeing the study met during the first calendar quarter of 2024 and cleared the trial to proceed to Part 2. Following the completion of the DSMB review, Sonnet announced initial safety data from the CIPN study. Pursuant to a license agreement the Company entered into with New Life Therapeutics Pte, Ltd. (“New Life”) of Singapore in May 2021, Sonnet and New Life will be jointly responsible for developing SON-080 in DPN. The objective will be to analyze the data and to consider initiating a Phase 2 study, pending the outcome of any partnering activity. SON-1210 (IL12-F H H SON-1411 (IL18-F H Sonnet has completed sequence confirmation for SON-3015 (anti-IL6-F H Liquidity The Company has incurred recurring losses and negative cash flows from operations since inception and it expects to incur losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates. The Company believes its cash of $ 3.6 The Company plans to secure additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources to carry out the Company’s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail or cease its operations until such funding is received. Various internal and external factors will affect whether and when the Company’s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company’s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company’s financial condition and future operations. Operations since inception have consisted primarily of organizing the Company, securing financing, developing technologies through research and development and conducting preclinical and clinical studies. The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies a. Basis of presentation The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (ASUs”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company’s financial position as of June 30, 2024 and its results of operations and cash flows for the three and nine months ended June 30, 2024 and 2023. The unaudited interim consolidated financial statements presented herein do not contain all of the required disclosures under U.S. GAAP for annual financial statements and should be read in conjunction with the annual audited consolidated financial statements and related notes of Sonnet as of and for the year ended September 30, 2023 included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. b. Consolidation The unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. c. Use of estimates The preparation of the unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited interim consolidated financial statements include the accrual of research and development expenses. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from management’s estimates. d. Incentive tax receivable Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by Subsidiary in Australia. The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period 0.5 0.1 0.3 0.5 0.8 0.8 e. Property and equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the consolidated statement of operations. f. Collaboration revenue Collaboration arrangements may contain multiple components, which may include (i) licenses; (ii) research and development activities; and (iii) the manufacturing and supply of certain materials. Payments pursuant to these arrangements may include non-refundable payments, upfront payments, milestone payments upon the achievement of significant regulatory and development events, sales milestones and royalties on product sales. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under a collaboration arrangement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as the Company satisfies each performance obligation. The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, and assessing the recognition of variable consideration. When consideration is received prior to the Company completing its performance obligation under the terms of a contract, a contract liability is recorded as deferred income. Deferred income expected to be recognized as revenue within the twelve months following the balance sheet date is classified as a current liability. In May 2021, the Company entered into a License Agreement (the “New Life Agreement”) with New Life. See Note 5 for further discussion of the New Life Agreement. g. Research and development expense Research and development expenses include all direct and indirect costs associated with the development of the Company’s biopharmaceutical products. These expenses include personnel costs, consulting fees, and payments to third parties for research, development, and manufacturing services. These costs are charged to expense as incurred. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the related project, based on the measure of progress as defined in the contract. Factors the Company considers in preparing the estimates include costs incurred by the service provider, milestones achieved, and other criteria related to the efforts of its service providers. Such estimates are subject to change as additional information becomes available. Depending on the timing of payment to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company will record a prepaid expense or accrued liability relating to these costs. Upfront milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Contingent development or regulatory milestone payments are recognized upon the related resolution of such contingencies. h. Other income The Company has participated in the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by the New Jersey Economic Development Authority. The Program enables approved biotechnology companies with unused net operating losses and unused research and development credits to sell these tax benefits for at least 80 4.3 i. Reverse stock split On August 31, 2023, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a 1-for-22 reverse stock split j. Net loss per share Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period (and potential shares of common stock that are exercisable for little or no consideration). Included in basic weighted-average number of shares of common stock outstanding during the three and nine months ended June 30, 2024 are the pre-funded October 2023 warrants to purchase 797,500 0.0001 1,500,000 137 0.0308 Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Schedule of Potentially Dilutive Securities 2024 2023 June 30, 2024 2023 Common stock warrants August 2021 112,429 128,500 Underwriter warrants August 2021 2,287 2,287 Chanticleer warrants 57 57 Series C warrants 18,391 36,778 Series 3 warrants 12,548 12,548 Unvested restricted stock units and awards 137,259 7,840 Common stock warrants February 2023 271,883 271,883 Underwriter warrants February 2023 15,466 44,190 Common stock private placement warrants June 2023 227,272 227,272 Placement agent warrants June 2023 6,818 6,818 Common stock warrants October 2023 2,840,000 — Underwriter warrants October 2023 85,312 — Placement agent warrants June 2024 113,140 — Common stock warrants June 2024 5,625,000 — Total anti-dilutive weighted average shares 9,467,862 738,173 k. Recent accounting pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	3. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities June 30, 2024 September 30, 2023 Compensation and benefits $ 189,095 $ 2,091,196 Research and development 753,497 913,145 Professional fees 204,344 224,031 Other 2,556 2,550 Accrued expenses and other current liabilities $ 1,149,492 $ 3,230,922 During the first quarter of 2024, the Company cancelled accrued but unpaid bonuses that had been awarded for fiscal years 2022 and 2023, which has been accounted for as a change in estimate. The cancellation of bonuses reduced research and development expenses by $ 1.0 0.9

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	4. Commitments and Contingencies Legal proceedings From time to time, the Company is a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of its business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company’s consolidated financial position, results of operations, or cash flows. License agreements In July 2012, the Company entered into a Discovery Collaboration Agreement (the “Collaboration Agreement”) with XOMA (US) LLC (“XOMA”), pursuant to which XOMA granted to the Company a non-exclusive, non-transferable license and/or right to use certain materials, technologies and related information related to discovery, optimization and development of antibodies and related proteins and to develop and commercialize products thereunder. The Company is obligated to make contingent milestone payments to XOMA totaling $ 3.8 0.5 No In August 2015, the Company entered into a License Agreement (the “ARES License Agreement”) with Ares Trading, a wholly-owned subsidiary of Merck KGaA (“ARES”). Under the terms of the ARES License Agreement, ARES has granted the Company a sublicensable, exclusive, worldwide, royalty-bearing license on proprietary patents to research, develop, use and commercialize products using atexakin alfa (“Atexakin”), a low dose formulation of human IL-6 in peripheral neuropathies and vascular complications. Pursuant to the ARES License Agreement, the Company will pay ARES high single-digit royalties on net sales of products sold by the Company. Royalties are payable on a product-by-product and country-by-country basis until the later of (i) a specified period of time after the first commercial sale in such country, and (ii) the last date on which such product is covered by a valid claim in such country. In January 2019, the Company entered into a Frame Services and License Agreement (the “Cellca Agreement”) with Sartorius Stedim Cellca GMBH (“Cellca”), pursuant to which Cellca has granted the Company a worldwide, non-exclusive, perpetual, non-transferable license to develop, manufacture or have manufactured, use, sell, import, export and/or otherwise commercialize product based on Cellca’s work to generate a specified transfected cell line and develop an upstream production process for such cell line. The Cellca Agreement is effective unless terminated by either party by giving six months notice, or by giving 14 days notice if terminated for good cause. The Company is obligated to make milestone payments to Cellca totaling up to $ 0.7 0.1 0.6 0.6 0.1 No In October 2021, the Company entered into a Non-Exclusive License Agreement (the “Brink Agreement”) with Brink Biologics Inc. (“Brink”), pursuant to which Brink has granted the Company a non-exclusive, non-transferable license and limited right to sublicense certain materials and related information to develop cell-based assays for batch, quality control, stability, efficacy, potency or any other type of assay required for production and commercialization of products. During the product development phase, the Company was obligated to make annual product development license fee payments of approximately $ 0.1 12,000 0.1 0.1 No 12,000 In February 2022, the Company entered into a Biological Materials License Agreement (the “InvivoGen Agreement”) with InvivoGen SAS (“InvivoGen”), pursuant to which InvivoGen has granted the Company a worldwide, non-exclusive license to use certain reporter cells for research, development and/or quality control purposes. The InvivoGen Agreement has an initial term of three years and may be extended for two additional three-year periods upon written notice by the Company and payment of an approximately € 0.1 0.1 No In March 2022, the Company entered into a Material Transfer and License Agreement (the “ProteoNic Agreement”) with ProteoNic B.V. (“ProteoNic”), pursuant to which ProteoNic has granted to the Company a non-exclusive, non-transferable, non-sublicensable (except as provided for in the ProteoNic Agreement) license for certain materials, including plasmids and DNA sequences used to generate the vectors used in the Company’s cell lines, for the Company’s use in research, development and commercialization of product. The Company incurred a $ 24,600 No Research and development agreement In December 2021, the Company entered into a Research and Development Agreement (the “Navigo Agreement”), as subsequently amended, with Navigo Proteins GmbH (“Navigo”), pursuant to which Navigo will perform specified evaluation and development procedures to evaluate certain materials to determine their commercial potential. Under the terms of the Navigo Agreement, the Company has granted Navigo a royalty-free, non-exclusive, worldwide, non-sublicensable, non-transferable right and license to use certain technology to perform the evaluation and development activities, and Navigo has granted the Company (i) an exclusive, worldwide, perpetual, irrevocable, sublicensable, transferable, royalty-free right and license to research, develop, use, sell, have sold, distribute, import or otherwise commercially exploit certain materials, and (ii) a non-exclusive, worldwide, perpetual, sublicensable, non-transferable right and license to make or have made such materials. The Company incurred a $ 0.1 1.0 0.2 0.3 No no Employment agreements The Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of benefits in the event of termination of employment either by the Company without cause or by the employee for good reason, both as defined in the contract. In addition, in the event of termination of employment following a change in control, as defined, either by the Company without cause or by the employee for good reason, any unvested portion of the employee’s initial stock option grant becomes immediately vested.

Collaboration Revenue

Collaboration Revenue	9 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration Revenue	5. Collaboration Revenue Under the New Life Agreement, the Company granted New Life an exclusive license (with the right to sublicense) to develop and commercialize pharmaceutical preparations containing a specific recombinant human IL-6, SON-080 (the “Compound”) (such preparations, the “Products”) for the prevention, treatment or palliation of diabetic peripheral neuropathy in humans (the “DPN Field”) in Malaysia, Singapore, Indonesia, Thailand, Philippines, Vietnam, Brunei, Myanmar, Lao PDR and Cambodia (the “Exclusive Territory”). New Life had the option to expand (1) the field of the exclusive license to include the prevention, treatment or palliation of chemotherapy-induced peripheral neuropathy in humans (the “CIPN Field”), which option was non-exclusive and expired on December 31, 2021; and/or (2) the territorial scope of the license to include the People’s Republic of China, Hong Kong and/or India, which option was exclusive and expired on December 31, 2021. The Company will retain all rights to manufacture Compounds and Products anywhere in the world. The Company and New Life shall enter into a follow-on supply agreement pursuant to which the Company shall supply to New Life Products for development and commercialization thereof in the DPN Field in the Exclusive Territory on terms to be negotiated by the parties. The Company will also assist in transferring certain preclinical and clinical development know-how that is instrumental in New Life’s ability to benefit from the license. New Life will bear the cost of, and be responsible for, among other things, conducting clinical studies and additional non-clinical studies and other developmental and regulatory activities for and commercializing Products in the DPN Field in the Exclusive Territory. New Life paid the Company a $ 0.5 0.5 New Life is also obligated to pay a non-refundable deferred license fee of an additional $ 1.0 19.0 12 30 The New Life Agreement will remain in effect on a Product-by-Product, country-by-country basis and will expire upon the expiration of the Royalty Term for the last-to-expire Product in the last-to-expire country, subject to (i) each party’s early termination rights including for material breach or insolvency or bankruptcy of the other party and (ii) the Company’s Buy Back Right and New Life’s Give Back Right (as defined below). In addition, New Life granted to the Company an exclusive option to buy back the rights granted by the Company to New Life and the Company granted New Life the right to give back the rights with respect to Products in the DPN Field in one or more countries in the Exclusive Territory on terms to be agreed upon, which options will expire upon the initiation of a Phase III Trial for the applicable Product. Revenue recognition The Company first assessed the New Life Agreement under ASC 808, Collaborative Arrangements Revenue from Contracts with Customers The Company determined the initial transaction price of the single performance obligation to be $ 1.0 Collaboration revenue from the single performance obligation is being recognized over the estimated performance of the R&D Activities. There was no 36,850 18,626 0.1

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit)	9 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Stockholders’ Equity (Deficit)	6. Stockholders’ Equity (Deficit) On May 2, 2024, the Company entered into a ChEF Purchase Agreement (the “Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”), each with Chardan Capital Markets LLC (“Chardan”) related to a “ChEF,” Chardan’s committed equity facility (the “Facility”). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to the lesser of (i) $ 25.0 622,168 19.99 4 37,654 0.1 0.4 On October 26, 2023, the Company closed a public offering of common stock and certain warrants through Chardan Capital Markets, LLC and Ladenburg Thalmann & Co. Inc. as underwriters, for net proceeds of $ 3.9 1,306,250 1,537,500 5,687,500 1.60 1.5999 1.60 1.20 0.0001 85,312 2.00 On June 30, 2023, the Company closed a registered direct offering of common stock (and common stock equivalents in lieu thereof) and a concurrent private placement of certain common stock warrants through Chardan Capital Markets, LLC as placement agent, for gross proceeds of $ 2.3 1.9 166,363 60,909 227,272 9.90 14.8478 1.55 0.0022 6,818 14.8478 On February 10, 2023, the Company closed a public offering of common stock and certain warrants through Chardan Capital Markets, LLC and EF Hutton, division of Benchmark Investments LLC as underwriters, for gross proceeds of $ 15.0 13.6 530,222 101,090 1,262,618 23.76 23.7578 23.76 0.0022 44,190 29.70 The Company entered into an At-the-Market Sales Agreement with BTIG, LLC (“BTIG”) on August 15, 2022 (the “2022 Sales Agreement”). Pursuant to the 2022 Sales Agreement, the Company could offer and sell, from time to time, through BTIG, as sales agent and/or principal, shares of its common stock having an aggregate offering price of up to $ 25.0 7.8 136,702 5.7 5.5 Common stock warrants As of June 30, 2024, the following equity-classified warrants and related terms were outstanding: Schedule of Warrants Outstanding Warrants Outstanding Exercise Price Expiration Date Common stock warrants August 2021 112,429 $ 261.80 August 24, 2026 Underwriter warrants August 2021 2,287 $ 327.25 August 19, 2026 Chanticleer warrants 57 $ 18,018.00 28,028.00 April 30, 2027 December 17, 2028 Series C warrants 18,391 $ 982.52 October 16, 2025 Series 3 warrants 12,548 $ 89.628 August 15, 2027 Common stock warrants February 2023 271,883 $ 23.76 February 10, 2028 Underwriter warrants February 2023 15,466 $ 29.70 February 8, 2028 Common stock private placement warrants June 2023 227,272 $ 1.55 June 21, 2029 Placement agent warrants June 2023 6,818 $ 14.8478 December 30, 2026 Common stock warrants October 2023 2,840,000 $ 1.20 October 27, 2028 Pre-funded warrants October 2023 797,500 $ 0.0001 — Underwriter warrants October 2023 85,312 $ 2.00 October 24, 2028 Placement agent warrants June 2024 113,140 $ 1.86 June 19, 2029 Common stock warrants June 2024 5,625,000 $ 1.55 June 21, 2029 Total 10,128,103 On June 19, 2024, the Company entered into inducement offer letter agreements with holders of certain existing warrants issued in October 2023 having an original exercise price of $ 1.60 2,828,500 1.20 3.4 2.9 1,500,000 5,625,000 2,840,000 1.60 1.20 227,272 14.8478 1.55 December 30, 2026 June 21, 2029 1.55 five years 113,140 1.86 five years During the nine months ended June 30, 2024, an aggregate of 768,724 754,312 2,863,500 1,500,000 3.0 34,458 During the nine months ended June 30, 2023, an aggregate of 1,014,872 519,492 137,998 332

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	7. Share-Based Compensation In April 2020, the Company adopted the 2020 Omnibus Equity Incentive Plan (the “Plan”). On January 1, 2024, the total number of shares authorized under the Plan increased to 137,260 one Restricted stock units and awards On January 1, 2024, 73,440 63,819 100 The Company recorded share-based compensation expense associated with the RSUs and RSAs in its accompanying unaudited interim consolidated statements of operations as follows: Schedule of Share-based Compensation Expense 2024 2023 2024 2023 Three Months Ended June 30, Nine Months Ended June 30, 2024 2023 2024 2023 Research and development $ 28,268 $ 24,554 $ 81,089 $ 102,807 General and administrative 32,127 25,451 89,706 95,813 Share Based Compensation $ 60,395 $ 50,005 $ 170,795 $ 198,620 The following table summarizes RSU activity under the Plan: Schedule of Restricted Stock Units Activity Weighted Average Grant RSU Date Fair Value Unvested balance at October 1, 2023 2,326 $ 21.78 Granted 73,440 $ 1.76 Vested (2,326 ) $ 21.78 Unvested balance at June 30, 2024 73,440 $ 1.76 As of June 30, 2024, total unrecognized compensation expense relating to unvested RSUs granted was $ 0.1 0.5 The following table summarizes RSA activity under the Plan: Schedule of Restricted Stock Awards Activity Weighted Average Grant RSA Date Fair Value Unvested balance at October 1, 2023 5,514 $ 28.27 Granted 63,819 $ 1.76 Vested (5,514 ) $ 28.27 Unvested balance at June 30, 2024 63,819 $ 1.76 As of June 30, 2024, total unrecognized compensation expense relating to unvested RSAs granted was $ 0.1 0.5

Income Taxes

Income Taxes	9 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes In August 2022, the U.S. enacted the Inflation Reduction Act of 2022 (“IRA”). The IRA contains a number of tax-related provisions that will be effective for tax years beginning after December 31, 2022, including a corporate alternative minimum tax of 15 1

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events The Company has evaluated subsequent events from the balance sheet date through August 14, 2024, the date at which the unaudited interim consolidated financial statements were available to be issued.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of presentation	a. Basis of presentation The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (ASUs”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company’s financial position as of June 30, 2024 and its results of operations and cash flows for the three and nine months ended June 30, 2024 and 2023. The unaudited interim consolidated financial statements presented herein do not contain all of the required disclosures under U.S. GAAP for annual financial statements and should be read in conjunction with the annual audited consolidated financial statements and related notes of Sonnet as of and for the year ended September 30, 2023 included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
Consolidation	b. Consolidation The unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of estimates	c. Use of estimates The preparation of the unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited interim consolidated financial statements include the accrual of research and development expenses. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from management’s estimates.
Incentive tax receivable	d. Incentive tax receivable Subsidiary is eligible to participate in an Australian research and development tax incentive program. As part of this program, Subsidiary is eligible to receive a cash refund from the Australian Taxation Office for a percentage of the research and development costs expended by Subsidiary in Australia. The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period 0.5 0.1 0.3 0.5 0.8 0.8
Property and equipment	e. Property and equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the consolidated statement of operations.
Collaboration revenue	f. Collaboration revenue Collaboration arrangements may contain multiple components, which may include (i) licenses; (ii) research and development activities; and (iii) the manufacturing and supply of certain materials. Payments pursuant to these arrangements may include non-refundable payments, upfront payments, milestone payments upon the achievement of significant regulatory and development events, sales milestones and royalties on product sales. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under a collaboration arrangement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as the Company satisfies each performance obligation. The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, and assessing the recognition of variable consideration. When consideration is received prior to the Company completing its performance obligation under the terms of a contract, a contract liability is recorded as deferred income. Deferred income expected to be recognized as revenue within the twelve months following the balance sheet date is classified as a current liability. In May 2021, the Company entered into a License Agreement (the “New Life Agreement”) with New Life. See Note 5 for further discussion of the New Life Agreement.
Research and development expense	g. Research and development expense Research and development expenses include all direct and indirect costs associated with the development of the Company’s biopharmaceutical products. These expenses include personnel costs, consulting fees, and payments to third parties for research, development, and manufacturing services. These costs are charged to expense as incurred. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the related project, based on the measure of progress as defined in the contract. Factors the Company considers in preparing the estimates include costs incurred by the service provider, milestones achieved, and other criteria related to the efforts of its service providers. Such estimates are subject to change as additional information becomes available. Depending on the timing of payment to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company will record a prepaid expense or accrued liability relating to these costs. Upfront milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Contingent development or regulatory milestone payments are recognized upon the related resolution of such contingencies.
Other income	h. Other income The Company has participated in the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by the New Jersey Economic Development Authority. The Program enables approved biotechnology companies with unused net operating losses and unused research and development credits to sell these tax benefits for at least 80 4.3
Reverse stock split	i. Reverse stock split On August 31, 2023, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a 1-for-22 reverse stock split
Net loss per share	j. Net loss per share Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period (and potential shares of common stock that are exercisable for little or no consideration). Included in basic weighted-average number of shares of common stock outstanding during the three and nine months ended June 30, 2024 are the pre-funded October 2023 warrants to purchase 797,500 0.0001 1,500,000 137 0.0308 Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Schedule of Potentially Dilutive Securities 2024 2023 June 30, 2024 2023 Common stock warrants August 2021 112,429 128,500 Underwriter warrants August 2021 2,287 2,287 Chanticleer warrants 57 57 Series C warrants 18,391 36,778 Series 3 warrants 12,548 12,548 Unvested restricted stock units and awards 137,259 7,840 Common stock warrants February 2023 271,883 271,883 Underwriter warrants February 2023 15,466 44,190 Common stock private placement warrants June 2023 227,272 227,272 Placement agent warrants June 2023 6,818 6,818 Common stock warrants October 2023 2,840,000 — Underwriter warrants October 2023 85,312 — Placement agent warrants June 2024 113,140 — Common stock warrants June 2024 5,625,000 — Total anti-dilutive weighted average shares 9,467,862 738,173
Recent accounting pronouncements	k. Recent accounting pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of Potentially Dilutive Securities	The following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they would be anti-dilutive: Schedule of Potentially Dilutive Securities 2024 2023 June 30, 2024 2023 Common stock warrants August 2021 112,429 128,500 Underwriter warrants August 2021 2,287 2,287 Chanticleer warrants 57 57 Series C warrants 18,391 36,778 Series 3 warrants 12,548 12,548 Unvested restricted stock units and awards 137,259 7,840 Common stock warrants February 2023 271,883 271,883 Underwriter warrants February 2023 15,466 44,190 Common stock private placement warrants June 2023 227,272 227,272 Placement agent warrants June 2023 6,818 6,818 Common stock warrants October 2023 2,840,000 — Underwriter warrants October 2023 85,312 — Placement agent warrants June 2024 113,140 — Common stock warrants June 2024 5,625,000 — Total anti-dilutive weighted average shares 9,467,862 738,173

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities June 30, 2024 September 30, 2023 Compensation and benefits $ 189,095 $ 2,091,196 Research and development 753,497 913,145 Professional fees 204,344 224,031 Other 2,556 2,550 Accrued expenses and other current liabilities $ 1,149,492 $ 3,230,922

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) (Tables)	9 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Warrants Outstanding	As of June 30, 2024, the following equity-classified warrants and related terms were outstanding: Schedule of Warrants Outstanding Warrants Outstanding Exercise Price Expiration Date Common stock warrants August 2021 112,429 $ 261.80 August 24, 2026 Underwriter warrants August 2021 2,287 $ 327.25 August 19, 2026 Chanticleer warrants 57 $ 18,018.00 28,028.00 April 30, 2027 December 17, 2028 Series C warrants 18,391 $ 982.52 October 16, 2025 Series 3 warrants 12,548 $ 89.628 August 15, 2027 Common stock warrants February 2023 271,883 $ 23.76 February 10, 2028 Underwriter warrants February 2023 15,466 $ 29.70 February 8, 2028 Common stock private placement warrants June 2023 227,272 $ 1.55 June 21, 2029 Placement agent warrants June 2023 6,818 $ 14.8478 December 30, 2026 Common stock warrants October 2023 2,840,000 $ 1.20 October 27, 2028 Pre-funded warrants October 2023 797,500 $ 0.0001 — Underwriter warrants October 2023 85,312 $ 2.00 October 24, 2028 Placement agent warrants June 2024 113,140 $ 1.86 June 19, 2029 Common stock warrants June 2024 5,625,000 $ 1.55 June 21, 2029 Total 10,128,103

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Compensation Expense	The Company recorded share-based compensation expense associated with the RSUs and RSAs in its accompanying unaudited interim consolidated statements of operations as follows: Schedule of Share-based Compensation Expense 2024 2023 2024 2023 Three Months Ended June 30, Nine Months Ended June 30, 2024 2023 2024 2023 Research and development $ 28,268 $ 24,554 $ 81,089 $ 102,807 General and administrative 32,127 25,451 89,706 95,813 Share Based Compensation $ 60,395 $ 50,005 $ 170,795 $ 198,620
Schedule of Restricted Stock Units Activity	The following table summarizes RSU activity under the Plan: Schedule of Restricted Stock Units Activity Weighted Average Grant RSU Date Fair Value Unvested balance at October 1, 2023 2,326 $ 21.78 Granted 73,440 $ 1.76 Vested (2,326 ) $ 21.78 Unvested balance at June 30, 2024 73,440 $ 1.76
Schedule of Restricted Stock Awards Activity	The following table summarizes RSA activity under the Plan: Schedule of Restricted Stock Awards Activity Weighted Average Grant RSA Date Fair Value Unvested balance at October 1, 2023 5,514 $ 28.27 Granted 63,819 $ 1.76 Vested (5,514 ) $ 28.27 Unvested balance at June 30, 2024 63,819 $ 1.76

Organization and Description _2

Organization and Description of Business (Details Narrative) - USD ($)	Jun. 30, 2024	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 3,554,331	$ 2,274,259

Schedule of Potentially Dilutiv

Schedule of Potentially Dilutive Securities (Details) - shares	9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	9,467,862	738,173
Common Stock Warrants August 2021 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	112,429	128,500
Underwriter Warrants August 2021 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	2,287	2,287
Chanticleer Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	57	57
Series C Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	18,391	36,778
Series 3 Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	12,548	12,548
Unvested Restricted Stock Units And Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	137,259	7,840
Common Stock Warrants February 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	271,883	271,883
Underwriter Warrants February 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	15,466	44,190
Common Stock Private Placement Warrants June 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	227,272	227,272
PA Warrants June 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	6,818	6,818
Common Stock Warrants October 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	2,840,000
Underwriter Warrants October 2023 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	85,312
PA Warrants June 2024 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	113,140
Common Stock Warrants June 2024 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive weighted average shares	5,625,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2023	Dec. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2023
Property, Plant and Equipment [Line Items]
Incentive tax receivable, description					The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period
Incentive tax receivable			$ 519,610		$ 519,610		$ 786,574
Cash refund (payment) related to tax incentive program			100,000	$ (300,000)	500,000	$ 800,000
Proceeds from income tax refunds		$ 800,000
Other income					$ 4,327,946
Reverse stock split	1-for-22 reverse stock split
Warrant, shares			10,128,103		10,128,103
Prefunded Warrant [Member] | October Offering [Member]
Property, Plant and Equipment [Line Items]
Warrants to purchase			797,500		797,500
Exercise price			$ 0.0001		$ 0.0001
Warrant, shares			1,500,000		1,500,000
Series B Warrant [Member]
Property, Plant and Equipment [Line Items]
Warrants to purchase				137		137
Exercise price				$ 0.0308		$ 0.0308
Minimum [Member]
Property, Plant and Equipment [Line Items]
Research and development credits tax benefits					80%
Research and Development Tax Incentive Program [Member]
Property, Plant and Equipment [Line Items]
Incentive tax receivable			$ 500,000		$ 500,000

Schedule of Accrued Expenses an

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Jun. 30, 2024	Sep. 30, 2023
Payables and Accruals [Abstract]
Compensation and benefits	$ 189,095	$ 2,091,196
Research and development	753,497	913,145
Professional fees	204,344	224,031
Other	2,556	2,550
Accrued expenses and other current liabilities	$ 1,149,492	$ 3,230,922

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details Narrative) $ in Millions	9 Months Ended
	Jun. 30, 2024 USD ($)
Payables and Accruals [Abstract]
Reduced research and development expenses	$ 1
Reduced general and administrative expenses	$ 0.9

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) € in Millions	1 Months Ended			3 Months Ended		9 Months Ended
	Apr. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 EUR (€)	Nov. 30, 2022 USD ($)	Jan. 31, 2019 USD ($)	Jul. 31, 2012 USD ($)
Loss Contingencies [Line Items]
Payment to acquire in process research and development						$ 12,000	$ 273,250
Discovery Collaboration Agreements [Member] | XOMA [Member]
Loss Contingencies [Line Items]
Milestone payments											$ 3,800,000
Discovery Collaboration Agreements [Member] | XOMA [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fee	$ 500,000			$ 0	$ 0	$ 0	0
Cellca Agreement [Member]
Loss Contingencies [Line Items]
Description of milestone payments						The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised
Cellca Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Milestone payments										$ 700,000
The Cellca Agreement [Member]
Loss Contingencies [Line Items]
Milestone payments				600,000		$ 600,000
The Cellca Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				600,000		600,000
The Cellca Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				100,000		100,000
The Cellca Agreement [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees	$ 100,000			0	0	0	0
The Brink Agreement [Member]
Loss Contingencies [Line Items]
Payment of annual license fee									$ 12,000
Commercial product license fee payment obligation				100,000		100,000
The Brink Agreement [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fee				0	0	12,000	12,000
Development license fee payments				100,000		100,000
InvivoGen Agreement [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				100,000		100,000		€ 0.1
License fees				0	0	0	0
ProteoNic Agreement [Member]
Loss Contingencies [Line Items]
License fees		$ 24,600		0		0
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member]
Loss Contingencies [Line Items]
Milestone payments			$ 1,000,000
Payment to acquire in process research and development			$ 100,000
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member] | Research and Development Expense [Member]
Loss Contingencies [Line Items]
Milestone payments				0	0	0	0
License fees				$ 0	$ 200,000	$ 0	$ 300,000

Collaboration Revenue (Details

Collaboration Revenue (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Jun. 30, 2021	Aug. 31, 2020	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collavorative arrangement right and obligation					New Life is also obligated to pay a non-refundable deferred license fee of an additional $1.0 million at the time of the satisfaction of certain milestones, as well as potential additional milestone payments to the Company of up to $19.0 million subject to the achievement of certain development and commercialization milestones. In addition, during the Royalty Term (as defined below), New Life is obligated to pay the Company tiered double-digit royalties ranging from 12% to 30% based on annual net sales of Products in the Exclusive Territory. The “Royalty Term” means, on a Product-by-Product and a country-by-country basis in the Exclusive Territory, the period commencing on the date of the first commercial sale (subject to certain conditions) of such Product in such country in the Exclusive Territory and continuing until New Life ceases commercialization of such Product in the DIPN Field
Performance obligation					$ 1,000,000
Collaboration revenue				$ 36,850	18,626	$ 110,550
License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds for negotiate license agreement		$ 500,000
New Life Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds for negotiate license agreement	$ 500,000
Future milestone payments			1,000,000		1,000,000
Milestone payments			$ 19,000,000		$ 19,000,000
New Life Agreement [Member] | Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties, percentage			12%		12%
New Life Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties, percentage			30%		30%

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details)	Jun. 30, 2024 $ / shares shares
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	10,128,103
Common Stock Warrants August 2021 [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	112,429
Exercise Price | $ / shares	$ 261.80
Expiration date	Aug. 24, 2026
Underwriter Warrants August 2021 [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	2,287
Exercise Price | $ / shares	$ 327.25
Expiration date	Aug. 19, 2026
Chanticleer Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	57
Chanticleer Warrants [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares	$ 18,018
Expiration date	Apr. 30, 2027
Chanticleer Warrants [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price | $ / shares	$ 28,028
Expiration date	Dec. 17, 2028
Series C Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	18,391
Exercise Price | $ / shares	$ 982.52
Expiration date	Oct. 16, 2025
Series 3 Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	12,548
Exercise Price | $ / shares	$ 89.628
Expiration date	Aug. 15, 2027
Common Stock Warrants February 2023 [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	271,883
Exercise Price | $ / shares	$ 23.76
Expiration date	Feb. 10, 2028
Underwriter Warrant February 2023 [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	15,466
Exercise Price | $ / shares	$ 29.70
Expiration date	Feb. 08, 2028
Common Stock Private Placement Warrants June 2023 [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	227,272
Exercise Price | $ / shares	$ 1.55
Expiration date	Jun. 21, 2029
PA Warrants June 2023 [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	6,818
Exercise Price | $ / shares	$ 14.8478
Expiration date	Dec. 30, 2026
Common Stock Warrants October 2023 [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	2,840,000
Exercise Price | $ / shares	$ 1.20
Expiration date	Oct. 27, 2028
Prefunded Warrants October 2023 [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	797,500
Exercise Price | $ / shares	$ 0.0001
Underwriter Warrants October 2023 [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	85,312
Exercise Price | $ / shares	$ 2
Expiration date	Oct. 24, 2028
PA Warrants June 2024 [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	113,140
Exercise Price | $ / shares	$ 1.86
Expiration date	Jun. 19, 2029
Common Stock Warrants June 2024 [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding | shares	5,625,000
Exercise Price | $ / shares	$ 1.55
Expiration date	Jun. 21, 2029

Stockholders_ Equity (Deficit_2

Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)								1 Months Ended	3 Months Ended					9 Months Ended
	Jun. 21, 2024	Jun. 19, 2024	May 02, 2024	Oct. 26, 2023	Jun. 30, 2023	Feb. 10, 2023	Aug. 15, 2022	Oct. 31, 2023	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2024	Jun. 30, 2023	Dec. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares, value									$ 62,019	$ 3,916,943	$ 1,945,677	$ 14,515,968	$ 4,452,012
Gross proceeds from sale agreement						$ 15,000,000
Financing costs incurred														$ 157,500
Proceeds from sale of common stock						$ 13,600,000								$ 3,899,157	21,024,070
Warrant, shares									10,128,103					10,128,103
Proceeds from warrant exercises														$ 3,002,968	$ 849
Underwriter Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued						44,190
Exercise price						$ 29.70
Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued					166,363
Warrant issued					227,272						227,272				227,272
Sales price, per share					$ 9.90						$ 9.90				$ 9.90
Warrants exercise price reduced														$ 1.55
Gross proceeds from private placement					$ 2,300,000
Net proceeds from issuance of private placement					$ 1,900,000
October Offering [Member] | Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from sale of common stock				$ 3,900,000
Warrant issued				85,312
Exercise price				$ 2
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares, value									$ 4	$ 131	$ 17	$ 56	$ 11
Number of shares issued									37,654	1,306,250	166,364	557,083	109,841
Sales price, per share						$ 23.76
Net share settlement of warrants, shares									739,950	14,362	508,834	10,521	137
Common Stock [Member] | Investors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued						530,222
Warrant issued						1,262,618
Common Stock [Member] | October Offering [Member] | Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of stock, shares				1,306,250
Exercise price				$ 0.0001
Prefunded Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales price, per share						$ 23.7578
Exercisable price per share						$ 0.0022
Prefunded Warrant [Member] | Investors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued						101,090
Prefunded Warrant [Member] | October Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued									797,500					797,500
Exercise price									$ 0.0001					$ 0.0001
Warrant, shares									1,500,000					1,500,000
Prefunded Warrant [Member] | October Offering [Member] | Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued				1,537,500
Sales price, per share				$ 1.5999
Common Warrant [Member] | October Offering [Member] | Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued				5,687,500
Sales price, per share				$ 1.60
Exercise price				$ 1.60
Warrants exercise price reduced														$ 1.20
Common Stock Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued														754,312	519,492
Warrant, shares									1,500,000					1,500,000
Net share settlement of warrants, shares														768,724	1,014,872
Number of warrant exercised														2,863,500	137,998
Proceeds from warrant exercises														$ 3,000,000
Number of warrant expired															332
Common Stock Warrants [Member] | Holder [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Forfeited warrants, shares														34,458
Purchase And Registration Rights Agreement [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares, value			$ 25,000,000
Number of shares issued			622,168
Sale of stock, percentage			19.99%
Volume weighted average price discount percentage			4%
Sale of stock, shares									37,654					37,654
Gross proceeds from sale agreement									$ 100,000					$ 100,000
Purchase Agreement [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Financing costs incurred									$ 400,000					$ 400,000
2022 Sales Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares, value							$ 7,800,000
2022 Sales Agreement [Member] | Underwriter Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued																6,818
2022 Sales Agreement [Member] | BTIG, LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares, value							$ 25,000,000
Sale of stock, shares															136,702
Gross proceeds from sale agreement															$ 5,700,000
Proceeds from sale of common stock															$ 5,500,000
2022 Sales Agreement [Member] | Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price					$ 0.0022						$ 0.0022				$ 0.0022
2022 Sales Agreement [Member] | Prefunded Warrant [Member] | Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued					60,909						60,909				60,909
2022 Sales Agreement [Member] | Common Warrant [Member] | Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price																$ 14.8478
Inducement Offer Letter Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price								$ 1.60
Warrants exercise price reduced								$ 1.20
Aggregate number of shares issued								2,828,500
Gross proceeds from sale agreement	$ 3,400,000
Net proceeds from sale agreement	$ 2,900,000
Warrant, shares									1,500,000					1,500,000
Inducement Offer Letter Agreements [Member] | Placement Agent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued		113,140
Exercise price		$ 1.86
Expire year		5 years
Inducement Offer Letter Agreements [Member] | New Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, shares		5,625,000
Inducement Offer Letter Agreements [Member] | Existing Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price								$ 1.60
Warrants exercise price reduced		$ 1.20
Warrant, shares		2,840,000
Inducement Offer Letter Agreements [Member] | Existing Warrant Issued In June 2023 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, shares					227,272						227,272				227,272
Inducement Offer Letter Agreements [Member] | Existing Warrant Issued In June 2023 [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price					$ 14.8478						$ 14.8478				$ 14.8478
Warrant expiration date					Jun. 21, 2029						Jun. 21, 2029				Jun. 21, 2029
Inducement Offer Letter Agreements [Member] | Existing Warrant Issued In June 2023 [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price									$ 1.55					$ 1.55
Warrant expiration date					Dec. 30, 2026						Dec. 30, 2026				Dec. 30, 2026
Inducement Offer Letter Agreements [Member] | New Common Stock Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price		$ 1.55
Expire year		5 years

Schedule of Share-based Compens

Schedule of Share-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share Based Compensation	$ 60,395	$ 50,005	$ 170,795	$ 198,620
Restricted Stock Units (RSUs) [Member] | Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share Based Compensation	28,268	24,554	81,089	102,807
Restricted Stock Units (RSUs) [Member] | General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share Based Compensation	$ 32,127	$ 25,451	$ 89,706	$ 95,813

Schedule of Restricted Stock Un

Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares		9 Months Ended
	Jan. 01, 2024	Jun. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
RSU, Unvested Beginning Balance		2,326
Weighted Average Grant Date Fair Value, Unvested Beginning Balance		$ 21.78
RSU, Granted	73,440	73,440
Weighted Average Grant Date Fair Value, Granted		$ 1.76
RSU, Vested		(2,326)
Weighted Average Grant Date Fair Value, Vested		$ 21.78
RSU, Unvested Ending Balance		73,440
Weighted Average Grant Date Fair Value, Unvested Ending Balance		$ 1.76

Schedule of Restricted Stock Aw

Schedule of Restricted Stock Awards Activity (Details) - Restricted Stock Awards (RSA) [Member] - $ / shares		9 Months Ended
	Jan. 01, 2024	Jun. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
RSU, Unvested Beginning Balance		5,514
Weighted Average Grant Date Fair Value, Unvested Beginning Balance		$ 28.27
RSA, Granted	63,819	63,819
Weighted Average Grant Date Fair Value, Granted		$ 1.76
RSA, Vested		(5,514)
Weighted Average Grant Date Fair Value, Vested		$ 28.27
RSU, Unvested Ending Balance		63,819
Weighted Average Grant Date Fair Value, Unvested Ending Balance		$ 1.76

Share-Based Compensation (Detai

Share-Based Compensation (Details Narrative) - USD ($) $ in Millions			9 Months Ended
	Jan. 01, 2025	Jan. 01, 2024	Jun. 30, 2024
Forecast [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting percentage	100%
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares granted		73,440	73,440
Unrecognized compensation expense			$ 0.1
Weighted average period			6 months
Restricted Stock Awards (RSA) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares granted		63,819	63,819
Unrecognized compensation expense			$ 0.1
Weighted average period			6 months
2020 Omnibus Equity Incentive Plan [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for issuance		137,260

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	Aug. 31, 2022
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Excise tax	1%
Minimum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Corporate alternative tax	15%